Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.73 |
| ▸ | PTGES | O14684 | 1/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | PDE5A | O76074 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CA3 | P07451 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342351 | 0.90 | PTGS2 (0.90) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL3096416 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| Mavacoxib SCHEMBL212699 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL152885 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL3246379 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL3900112 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| Celecoxib SCHEMBL3708 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL6013946 | 0.84 | PTGS2 (0.80) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| Celecoxib SCHEMBL3669597 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL18916270 | 0.84 | PTGS2 (0.80) | PTGS2PTGS1CYP2C9PDPK1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1281709-B1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | URIACH Y COMPANIA S A J (ES) | 2005-02-16 | — | — | EP | claimed |
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | J. URIACH & CIA, S.A. (ES) | 2003-06-19 | — | — | US | claimed |
| EP-1281709-A1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-02-05 | — | — | EP | claimed |
| EP-1281709-B1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | URIACH Y COMPANIA S A J (ES) | 2005-02-16 | — | — | EP | disclosed |
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | J. URIACH & CIA, S.A. (ES) | 2003-06-19 | — | — | US | disclosed |
| EP-1281709-A1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | IL1B, IL1A, NFKBIA | PTGS2 23/4885PTGS1 7/4885CYP2C9 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.